US Stock MarketDetailed Quotes

PLX Protalix Biotherapeutics

Watchlist
  • 1.760
  • +0.020+1.15%
Close Dec 20 16:00 ET
  • 1.760
  • 0.0000.00%
Post 18:22 ET
129.60MMarket Cap-11.73P/E (TTM)

Protalix Biotherapeutics Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
159.60%4.11M
-172.59%-3.61M
239.69%4.19M
94.73%-1.32M
237.69%3.6M
25.16%-6.89M
167.60%4.97M
48.57%-3M
-143.07%-25M
48.67%-2.61M
Net income from continuing operations
274.73%3.24M
-111.39%-2.2M
-46.76%-4.6M
155.68%8.31M
-61.60%-6.04M
48.08%-1.85M
462.56%19.34M
-36.96%-3.13M
45.88%-14.93M
43.90%-3.74M
Operating gains losses
102.78%3K
109.09%1K
-75.00%5K
92.96%-38K
139.35%61K
-325.00%-108K
97.88%-11K
-76.47%20K
-166.42%-540K
-2,037.50%-155K
Depreciation and amortization
7.87%329K
8.87%319K
15.00%322K
9.67%1.19M
13.82%313K
11.72%305K
9.33%293K
3.70%280K
-2.86%1.09M
6.18%275K
Deferred tax
1,065.79%443K
97.80%-69K
---138K
---3.09M
--0
--38K
---3.13M
--0
--0
--0
Other non cash items
483.95%1.15M
-21.74%-504K
-4,181.82%-471K
12.92%-600K
-27.06%124K
-464.15%-299K
39.39%-414K
91.06%-11K
-122.30%-689K
-57.82%170K
Change In working capital
72.42%-1.67M
81.36%-2.15M
1,251.57%8.08M
12.28%-10.54M
2,491.33%7.77M
4.08%-6.07M
-738.20%-11.54M
84.78%-702K
-221.35%-12.02M
-39.02%300K
-Change in receivables
294.50%8.38M
-90.44%-7.05M
-54.33%1.75M
64.15%-428K
-16.41%3.76M
25.33%-4.31M
-254.98%-3.7M
265.21%3.82M
-15.70%-1.19M
47.81%4.5M
-Change in inventory
280.70%3.52M
143.56%1.63M
5.66%-3.3M
-294.87%-2.24M
213.20%2.54M
-200.15%-1.95M
667.82%668K
-357.28%-3.5M
123.60%1.15M
30.46%-2.24M
-Change in payables and accrued expense
-590.96%-869K
-50.97%1.61M
-500.57%-1.41M
210.22%5.3M
503.01%1.48M
-58.45%177K
185.39%3.29M
134.92%353K
-301.43%-4.8M
-127.83%-366K
-Change in other current assets
-177.78%-7K
200.00%6K
55.56%14K
360.00%13K
-96.00%1K
133.33%9K
---6K
--9K
-102.07%-5K
-65.75%25K
-Change in other current liabilities
----
----
----
--0
----
----
----
----
--0
----
-Change in other working capital
----
114.05%1.66M
895.32%11.04M
-84.00%-13.18M
--0
--0
-589,600.00%-11.79M
47.54%-1.39M
-154.13%-7.16M
-125.87%-1.62M
Cash from discontinued investing activities
Operating cash flow
159.60%4.11M
-172.59%-3.61M
239.69%4.19M
94.73%-1.32M
237.69%3.6M
25.16%-6.89M
167.60%4.97M
48.57%-3M
-143.07%-25M
48.67%-2.61M
Investing cash flow
Cash flow from continuing investing activities
197.36%20.33M
18.92%-180K
-112.81%-606K
-231.90%-16.71M
-106.90%-342K
-453.16%-20.88M
-162.18%-222K
129.11%4.73M
-126.61%-5.04M
-86.77%4.95M
Net PPE purchase and sale
81.21%-84K
15.69%-172K
-141.13%-598K
-82.96%-1.15M
-17.37%-250K
-670.69%-447K
-59.38%-204K
-8.30%-248K
55.33%-628K
52.46%-213K
Net investment purchase and sale
----
----
----
-208.40%-15.42M
--0
-440.33%-20.42M
--0
131.25%5M
-125.00%-5M
-86.78%5M
Net other investing changes
25.00%-9K
55.56%-8K
60.00%-8K
-123.95%-142K
-155.42%-92K
60.00%-12K
-103.71%-18K
28.57%-20K
81.35%593K
238.78%166K
Cash from discontinued investing activities
Investing cash flow
197.36%20.33M
18.92%-180K
-112.81%-606K
-231.90%-16.71M
-106.90%-342K
-453.16%-20.88M
-162.18%-222K
129.11%4.73M
-126.61%-5.04M
-86.77%4.95M
Financing cash flow
Cash flow from continuing financing activities
-20.42M
0
0
199.42%24.67M
0
0
10.43M
14.23M
-31.79%8.24M
200.72%4.08M
Net issuance payments of debt
----
----
----
--0
----
----
----
----
--0
----
Net common stock issuance
--0
--0
--0
190.85%23.95M
--0
--0
--9.72M
--14.23M
-82.17%8.24M
--4.08M
Proceeds from stock option exercised by employees
--0
----
----
35,500.00%712K
--0
--0
----
----
--2K
--0
Cash from discontinued financing activities
Financing cash flow
---20.42M
--0
--0
199.42%24.67M
--0
--0
294.74%10.43M
--14.23M
-31.79%8.24M
200.72%4.08M
Net cash flow
Beginning cash position
-51.44%23.4M
-17.64%27.21M
38.12%23.63M
-56.11%17.11M
90.37%20.41M
285.72%48.18M
95.62%33.04M
-56.11%17.11M
113.44%38.99M
0.73%10.72M
Current changes in cash
114.45%4.01M
-124.96%-3.79M
-77.57%3.58M
130.45%6.64M
-49.31%3.25M
-1,466.99%-27.77M
448.58%15.18M
172.29%15.97M
-205.23%-21.8M
-77.33%6.42M
Effect of exchange rate changes
77.78%-2K
44.44%-20K
83.33%-7K
-48.05%-114K
-3.85%-27K
---9K
10.00%-36K
-281.82%-42K
-1,383.33%-77K
-165.00%-26K
End cash Position
34.31%27.41M
-51.44%23.4M
-17.64%27.21M
38.12%23.63M
38.12%23.63M
90.37%20.41M
285.72%48.18M
95.62%33.04M
-56.11%17.11M
-56.11%17.11M
Free cash flow
154.78%4.02M
-179.30%-3.78M
210.60%3.59M
90.37%-2.47M
218.45%3.35M
20.81%-7.34M
163.72%4.77M
46.42%-3.25M
-118.22%-25.63M
48.98%-2.82M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
--
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 159.60%4.11M-172.59%-3.61M239.69%4.19M94.73%-1.32M237.69%3.6M25.16%-6.89M167.60%4.97M48.57%-3M-143.07%-25M48.67%-2.61M
Net income from continuing operations 274.73%3.24M-111.39%-2.2M-46.76%-4.6M155.68%8.31M-61.60%-6.04M48.08%-1.85M462.56%19.34M-36.96%-3.13M45.88%-14.93M43.90%-3.74M
Operating gains losses 102.78%3K109.09%1K-75.00%5K92.96%-38K139.35%61K-325.00%-108K97.88%-11K-76.47%20K-166.42%-540K-2,037.50%-155K
Depreciation and amortization 7.87%329K8.87%319K15.00%322K9.67%1.19M13.82%313K11.72%305K9.33%293K3.70%280K-2.86%1.09M6.18%275K
Deferred tax 1,065.79%443K97.80%-69K---138K---3.09M--0--38K---3.13M--0--0--0
Other non cash items 483.95%1.15M-21.74%-504K-4,181.82%-471K12.92%-600K-27.06%124K-464.15%-299K39.39%-414K91.06%-11K-122.30%-689K-57.82%170K
Change In working capital 72.42%-1.67M81.36%-2.15M1,251.57%8.08M12.28%-10.54M2,491.33%7.77M4.08%-6.07M-738.20%-11.54M84.78%-702K-221.35%-12.02M-39.02%300K
-Change in receivables 294.50%8.38M-90.44%-7.05M-54.33%1.75M64.15%-428K-16.41%3.76M25.33%-4.31M-254.98%-3.7M265.21%3.82M-15.70%-1.19M47.81%4.5M
-Change in inventory 280.70%3.52M143.56%1.63M5.66%-3.3M-294.87%-2.24M213.20%2.54M-200.15%-1.95M667.82%668K-357.28%-3.5M123.60%1.15M30.46%-2.24M
-Change in payables and accrued expense -590.96%-869K-50.97%1.61M-500.57%-1.41M210.22%5.3M503.01%1.48M-58.45%177K185.39%3.29M134.92%353K-301.43%-4.8M-127.83%-366K
-Change in other current assets -177.78%-7K200.00%6K55.56%14K360.00%13K-96.00%1K133.33%9K---6K--9K-102.07%-5K-65.75%25K
-Change in other current liabilities --------------0------------------0----
-Change in other working capital ----114.05%1.66M895.32%11.04M-84.00%-13.18M--0--0-589,600.00%-11.79M47.54%-1.39M-154.13%-7.16M-125.87%-1.62M
Cash from discontinued investing activities
Operating cash flow 159.60%4.11M-172.59%-3.61M239.69%4.19M94.73%-1.32M237.69%3.6M25.16%-6.89M167.60%4.97M48.57%-3M-143.07%-25M48.67%-2.61M
Investing cash flow
Cash flow from continuing investing activities 197.36%20.33M18.92%-180K-112.81%-606K-231.90%-16.71M-106.90%-342K-453.16%-20.88M-162.18%-222K129.11%4.73M-126.61%-5.04M-86.77%4.95M
Net PPE purchase and sale 81.21%-84K15.69%-172K-141.13%-598K-82.96%-1.15M-17.37%-250K-670.69%-447K-59.38%-204K-8.30%-248K55.33%-628K52.46%-213K
Net investment purchase and sale -------------208.40%-15.42M--0-440.33%-20.42M--0131.25%5M-125.00%-5M-86.78%5M
Net other investing changes 25.00%-9K55.56%-8K60.00%-8K-123.95%-142K-155.42%-92K60.00%-12K-103.71%-18K28.57%-20K81.35%593K238.78%166K
Cash from discontinued investing activities
Investing cash flow 197.36%20.33M18.92%-180K-112.81%-606K-231.90%-16.71M-106.90%-342K-453.16%-20.88M-162.18%-222K129.11%4.73M-126.61%-5.04M-86.77%4.95M
Financing cash flow
Cash flow from continuing financing activities -20.42M00199.42%24.67M0010.43M14.23M-31.79%8.24M200.72%4.08M
Net issuance payments of debt --------------0------------------0----
Net common stock issuance --0--0--0190.85%23.95M--0--0--9.72M--14.23M-82.17%8.24M--4.08M
Proceeds from stock option exercised by employees --0--------35,500.00%712K--0--0----------2K--0
Cash from discontinued financing activities
Financing cash flow ---20.42M--0--0199.42%24.67M--0--0294.74%10.43M--14.23M-31.79%8.24M200.72%4.08M
Net cash flow
Beginning cash position -51.44%23.4M-17.64%27.21M38.12%23.63M-56.11%17.11M90.37%20.41M285.72%48.18M95.62%33.04M-56.11%17.11M113.44%38.99M0.73%10.72M
Current changes in cash 114.45%4.01M-124.96%-3.79M-77.57%3.58M130.45%6.64M-49.31%3.25M-1,466.99%-27.77M448.58%15.18M172.29%15.97M-205.23%-21.8M-77.33%6.42M
Effect of exchange rate changes 77.78%-2K44.44%-20K83.33%-7K-48.05%-114K-3.85%-27K---9K10.00%-36K-281.82%-42K-1,383.33%-77K-165.00%-26K
End cash Position 34.31%27.41M-51.44%23.4M-17.64%27.21M38.12%23.63M38.12%23.63M90.37%20.41M285.72%48.18M95.62%33.04M-56.11%17.11M-56.11%17.11M
Free cash flow 154.78%4.02M-179.30%-3.78M210.60%3.59M90.37%-2.47M218.45%3.35M20.81%-7.34M163.72%4.77M46.42%-3.25M-118.22%-25.63M48.98%-2.82M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion------------
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.